复旦张江截至二零二四年六月三十日止六个月中期报告

<>® 11 1 IQVIA3-6%1.93.70%2,2143,4984,574 2 WHO4.21.5925.59266.693,0044,71811.95% 2 HPVHPV20030HPV-611 16 180.5%5%80%-90%TCABCA5ALA 75%-80%65%40 3 57.27%22016020%IARC1,92945723.7%IQVIA3,700 3() DNRADMEPITHPMIT PEG 1)® ®®®®20212017 ®®®® 2)复美達® 复美達®LED 1)® ®www.menet.com.cn263638.46% 1. 1. (1) ADCADC (2) ®复美達®II ®®®20212017 复美達®复美達® 1. (2) (3) EPR ® (4) 2. II WHOIII-IV Trop2SN38FDA018IAmerican Society of Clinical OncologyASCO HER2Her2BB05FDA022 DLL3BB05FZ-AD005I 1 2 3. 4. 4. 1 2 5. % 5040-4930-3920-29 6. 1. 1. 2. --1 3. 4. cGMPFDAEMAcGMPCAPA cGMP cGMP 5. P h o t o d y n a m i c T h e r a p y , P D TPhotodynamic Diagnosis, PDD antibacterial Photodynamic Therapy, aPDTPhotoimmunotherapy, PITPDT Intraoperative Molecular ImageIMIIXIMIIMI ® ®®20212017 HPVCINIIIII IIIII20192022 AKIIAK20212021 ALA NMIBCMIBCNMIBCTURBTNMIBCTURBTNMIBCTURBTNMIBC IIIARC202042 复美達®65%40复美達®505b(1)II复美達® ADC ADCADC ADCCD30-MCC-DM1CD30DM1DM1ADCCD30ADCETRIS®CD30-MMAEKadcyla®Her2-DM1/T-DM1ADCADC ADCTrop2Trop2SN38FDA018linkerMe-tooIIII linker-drugBB05Me-betterADCBB05ADC –Her2Her2BB05FDA022I2HER2BB05HER2IHER2 –Trop2Trop2BB05FZ-AD004ITROP-2BB05TROP-2TROP-2I –DLL3DLL3BB05FZ-AD005IDLL3ADCDLL3I ADCADC (Parkinson’s disease)50-60(WD-1603)2FDA505(b)(2)UGi-Pump®PCT (PBC)17 - 1. 2. 1. ®®复美達® 1. 1. 4+7 - ®复美達®®®9.37%®Doxil®®®600267®®CSOCSO®®45.83% 复美達®复美達®复美達®36.17% 144Trop2SN38FDA018IIIHer2BB05FDA022 NMPAGMP 1. ® ® 1. 2. 1. %%%117,527,1444.13174,262,3196.06-32.5620,384,3360.724,330,9800.15370.664,524,6500.161,521,7950.05197.3224,2390.0015,1260.0060.25Kintara491,649,48717.26228,496,0437.94115.17187,1890.01229,962,8127.99-99.92 1. (i) H 1,222,481,006 1. (ii) (iii) (iv) (v) (vi) A10% (1) (2)50% 1. (vi) 0.021,036,572,10020,731,442A710,572,10014,211,224H326,000,0006,520,000HHHH183171712-1716HAAH H[2008]897H10%10% [1993]045[2011]34810%H10% 1. (vi) A10%10% A H H[2014]81HH20% H (vii) 2.1)21,296,3990.75%2)3.4. 1. 279,219226,5037.95% (i)10,242138.0526(ii)2,524.3137276.549026,595.9483414.601639.5663% - 5% 1. (1)(2)(3) A d g e r oBiopharmaceuticals Holdings, IncAdgeroAdgeroDelMar Phamarceuticals, IncNASDAQDPMIDelmarDelmarAdergoDelmarKintara Therapeutics,IncNASDAQKTRAKintaraKintaraKintara12,592KintaraKintara24,239 2. I3.086IIA0.5786 A1.88584 I3.087IIA0.5787 A1.886 IIIIII3.0863025 A 1,025 123AH456789A 1011121314A 123 1)2)3)4)5) ---1-(vi) AAAAH A3,8003,277258523125 1. 2. 3. 3800A3.67%3,277258100120120120 4. 1.00% 5. 6. 8.830.050.078.958.83 7. A36.4C15,723,000 8. 7,572,100A 0A0AA0.00%0.00%15,723,000A0AA2.21%0.00% 8. A16.73A9.34A9.35 8. (1) (2) a)b)c)d)e)f)g)h)i)j)k)l)m)n) C1 (2) C.2.1 C.2.1 (3) C3 (4) 3.10(1)3.10(2)3.21 (5) 913911117,815,229116,719,641 (6) 79.77 1 2 (1) (2) 2 (3) 3 94.92 A 1 23 1234 123 123 3 A107,400.009,967.6197,432.3926,235.42 1A 2 3AA 4 55,845.262,212.87 624,830.7524,000830.750 1 2 3 25,000- 1234 19,611 19,611A19,475H136 5%10101010 571XV23336 123 (a)571XV78(b)352(c)C3 AC3 2024630 2024630 2024630 2024630 20246306 20246306 70,613,80568,329,921(129,051)167,262 70,484,75468,497,183 20246306 2024630620236306 36,864,50445,084,136–6,257,921 36,864,50451,342,057 36,864,50451,342,057 20246306 20246306 131,628129,974 (51)(c)26,585,009(58,174,165)(51)(c)1,195,895,9971,289,302,664 (51)(c)1,222,481,0061,231,128,499 20246306 20246306 2024630620236306 –66,861,643 –66,861,643 –(2,705,716)(5,489,073)(4,857,461) (5,489,073)(7,563,177) (5,489,073)59,298,466 –– 25,661,214(39,492,994)1,067,294,4321,187,769,137 20246306 20246306 20246306 20246306 199611115,295,000 200010205,295,00053,000,000 200011853,000,00053,000,0001 20021 20153,000,0000.10530,000,000 20028 13198,000,0000.10H71,000,000710,000,0000.1 20132 4142,000,000H1.7085,200,000852,000,0000.1 20131216H 20206 12120,000,0000.10A2020619104,300,0001,043,000,0000.1 20226 714,000,000H1,043,000,0001,029,000,000 20235 112021205A7,572,1000.1103,657,210 20246306 2024812 (8)(9)(11)(13)(22)(13)(18) (25) 20246306 (1) 200621515 201433 (2) 20246306202463020246306 (3) 111231 (4) (5) 20246306 (6) (7) (a) (b) (8) (a) (i) (1)(2)(3) 20246306 (8) (a) (i) (ii) 20246306 (8) (a) (ii) 12 12 12 20246306 (8) (a) (iii) (1)(2)(3) (b) (c) (9) (a) (b) 20246306 (9) (c) (d) (e) (10) (a) (b) 20246306 (10) (b) (c) (d) (11) (a) 20246306 (11) (b) (c)(15) (d) (12) (15) (13) (a) 47-50 (b) 5-10 20246306 (13) (c) 5-10 (d) 3-10 (e) (f) ••••• (g) (15) (14) 20246306 (15) (16) (a) (b) 20246306 (17) (18) (8) (a) (b) (c) (19) 20246306 (19) (20) (21) •• 20246306 (22) 12 (1)(2) (23) (1)(2)(3) 20246306 (24) (25) (a) (i) 20246306 (25) (b) (i) (ii) (iii) (1)15%25% 20246306 (a)2023GR202331000166)32024630615%2023630615%) 2021GR202132007432)320246 30 615%2023630615%) 2022GR202231000054)320